by admin@clickscount.co.za | Dec 2, 2024 | Trials
Protocol Title: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safetyof Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral SelectiveEstrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor orTamoxifen)...
by admin@clickscount.co.za | Dec 2, 2024 | Trials
Protocol Title: A Phase III, Two- Arm, Parallel, Randomized, Multi-Center,Open-Label, GlobalStudy to Determine the Efficacy of Volrustomig (MEDI5752) Versus Pembrolizumab inCombinationwith Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small...
by admin@clickscount.co.za | Dec 2, 2024 | Trials
Protocol Title: A Phase III, Randomized, Open-Label, Multicenter, Global Study ofVolrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinumplus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable PleuralMesothelioma...
by admin@clickscount.co.za | Nov 21, 2024 | Trials
Protocol Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre,International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy inParticipants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung CancerWhose Disease...
